Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries no "tag".
The protein has a calculated MW of 55.0 kDa. The protein migrates as 58 kDa±3 kDa under reducing (R) condition, and 58 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human IL-23A&IL-12B Heterodimer Protein, premium grade on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
The purity of Human IL-23A&IL-12B Heterodimer Protein, premium grade (Cat. No. ILB-H5219) is more than 85% and the molecular weight of this protein is around 50-70 kDa verified by SEC-MALS.
Human IL-23A&IL-12B Heterodimer Protein, premium grade (Cat. No. ILB-H5219) stimulates proliferation of Human IL-23 R/IL-12 R beta 1(Luc) HEK293 Reporter Cell. The specific activity of Human IL-23A&IL-12B Heterodimer Protein, premium grade is > 1.80 X 10^3 U/mg (QC tested).
Immobilized Human IL-23A&IL-12B Heterodimer Protein, premium grade (Cat. No. ILB-H5219) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human IL23A&IL12B P40 domain Antibody, Human IgG1 with a linear range of 0.02-1 ng/mL (QC tested).
Immobilized Human IL-23A&IL-12B Heterodimer Protein, premium grade (Cat. No. ILB-H5219) at 5 μg/mL (100 μL/well) can bind Human IL-12 R beta 1, Fc Tag (Cat. No. ILB-H5255) with a linear range of 0.2-3 ng/mL (Routinely tested).
Price(USD) : $185.00
Price(USD) : $370.00
Price(USD) : $2680.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Ustekinumab | C-340; CNTO-1275 | Approved | Johnson & Johnson Innovative Medicine | Stelara, 喜达诺 | United States | Plaque psoriasis | Janssen Biotech Inc | 2009-09-25 | Multiple Sclerosis; Plaque psoriasis; Dermatitis, Atopic; Crohn Disease; Hidradenitis Suppurativa; Common Variable Immunodeficiency; Uveitis; Colitis, Ulcerative; Arthritis, Psoriatic; Takayasu Arteritis; Lupus Erythematosus, Systemic; Psoriasis; Diabetes Mellitus, Type 1; Arthritis, Juvenile; Sjogren's Syndrome; Spondylitis, Ankylosing; Pouchitis; Ichthyosis; Dermatomyositis; Inflammatory Bowel Diseases; Type I Leukocyte Adhesion Defect; Polymyositis; Liver Cirrhosis, Biliary | Details |
Ustekinumab biosimilar(Formycon) | FYB-202 | Approved | Formycon AG | OTULFI | EU | Crohn Disease; Colitis, Ulcerative | Fresenius Kabi Deutschland Gmbh, Formycon AG | 2024-09-25 | Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
Ustekinumab Biosimilar (qyuns) | QX-001S; QX-001-S; HDM-3001 | Approved | Qyuns Therapeutics Co Ltd | Mainland China | Plaque psoriasis | Qyuns Therapeutics Co Ltd | 2024-10-29 | Psoriasis; Plaque psoriasis | Details | |
Ustekinumab Biosimilar(Celltrion) | CT-P43 | Approved | Celltrion Inc | Steqeyma, Steqeyma IV | Canada | Plaque psoriasis; Arthritis, Psoriatic; Crohn Disease | Celltrion Inc | 2024-08-01 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
Ustekinumab biosimilar (Biocon) | Approved | Biocon Biologics Ltd | Bmab 1200, Yesintek | United States | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease | Biocon Biologics Inc | 2024-11-29 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details | |
Ustekinumab biosimilar (Alvotech) | AVT04; AVT-04 | Approved | Alvotech hf | Jamteki, Uzpruvo, SELARSDI™, JamtekiTM, Ustekinumab BS (F) | Japan | Arthritis, Psoriatic; Psoriasis | Fuji Pharma Co Ltd | 2023-09-25 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
Ustekinumab biosimilar(Amgen) | ABP-654 | Approved | Amgen Inc | Wezlana, WEZLANA, wezenla | United States | Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic; Plaque psoriasis | Amgen Inc | 2023-10-31 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details |
Ustekinumab biosimilar(DM Bio) | DA-3115; DMB-3115 | Approved | Dong-A Pharmaceutical Co Ltd, Meiji Seika Pharma Co Ltd | IMULDOSA, Absimky | United States | Psoriasis | Dong-A ST Co Ltd, Meiji Seika Kaisha Ltd | 2024-10-11 | Psoriasis; Colitis, Ulcerative; Crohn Disease | Details |
Ustekinumab | C-340; CNTO-1275 | Approved | Johnson & Johnson Innovative Medicine | Stelara, 喜达诺 | United States | Plaque psoriasis | Janssen Biotech Inc | 2009-09-25 | Multiple Sclerosis; Plaque psoriasis; Dermatitis, Atopic; Crohn Disease; Hidradenitis Suppurativa; Common Variable Immunodeficiency; Uveitis; Colitis, Ulcerative; Arthritis, Psoriatic; Takayasu Arteritis; Lupus Erythematosus, Systemic; Psoriasis; Diabetes Mellitus, Type 1; Arthritis, Juvenile; Sjogren's Syndrome; Spondylitis, Ankylosing; Pouchitis; Ichthyosis; Dermatomyositis; Inflammatory Bowel Diseases; Type I Leukocyte Adhesion Defect; Polymyositis; Liver Cirrhosis, Biliary | Details |
Ustekinumab biosimilar(Formycon) | FYB-202 | Approved | Formycon AG | OTULFI | EU | Crohn Disease; Colitis, Ulcerative | Fresenius Kabi Deutschland Gmbh, Formycon AG | 2024-09-25 | Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
Ustekinumab Biosimilar (qyuns) | QX-001S; QX-001-S; HDM-3001 | Approved | Qyuns Therapeutics Co Ltd | Mainland China | Plaque psoriasis | Qyuns Therapeutics Co Ltd | 2024-10-29 | Psoriasis; Plaque psoriasis | Details | |
Ustekinumab Biosimilar(Celltrion) | CT-P43 | Approved | Celltrion Inc | Steqeyma, Steqeyma IV | Canada | Plaque psoriasis; Arthritis, Psoriatic; Crohn Disease | Celltrion Inc | 2024-08-01 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
Ustekinumab biosimilar (Biocon) | Approved | Biocon Biologics Ltd | Bmab 1200, Yesintek | United States | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease | Biocon Biologics Inc | 2024-11-29 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details | |
Ustekinumab biosimilar (Alvotech) | AVT04; AVT-04 | Approved | Alvotech hf | Jamteki, Uzpruvo, SELARSDI™, JamtekiTM, Ustekinumab BS (F) | Japan | Arthritis, Psoriatic; Psoriasis | Fuji Pharma Co Ltd | 2023-09-25 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
Ustekinumab biosimilar(Amgen) | ABP-654 | Approved | Amgen Inc | Wezlana, WEZLANA, wezenla | United States | Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic; Plaque psoriasis | Amgen Inc | 2023-10-31 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details |
Ustekinumab biosimilar(DM Bio) | DA-3115; DMB-3115 | Approved | Dong-A Pharmaceutical Co Ltd, Meiji Seika Pharma Co Ltd | IMULDOSA, Absimky | United States | Psoriasis | Dong-A ST Co Ltd, Meiji Seika Kaisha Ltd | 2024-10-11 | Psoriasis; Colitis, Ulcerative; Crohn Disease | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Brazikumab | AMG-139; MEDI-2070; Anti-IL-23-MAb (Amgen) | Phase 2 Clinical | Amgen Inc | Inflammatory Bowel Diseases; Psoriasis; Colitis, Ulcerative; Crohn Disease | Details |
mRNA-2752 | mRNA-2752 | Phase 1 Clinical | Moderna Inc, Astrazeneca Plc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
SFA-002 | SFA-002; SFA002 | Phase 1 Clinical | Arthritis, Rheumatoid; Plaque psoriasis | Details | |
IL-23/CGRP bispecific antibody (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Autoimmune Diseases | Details | |
Ustekinumab biosimilar (Curateq Biologics) | BP38; BP-38 | Phase 1 Clinical | CuraTeQ Biologics Pvt Ltd | Psoriasis | Details |
Ustekinumab Biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Autoimmune Diseases | Details | |
Ustekinumab biosimilar(Rani Therapeutics) | RT-111 | Phase 1 Clinical | Rani Therapeutics Llc | Psoriasis | Details |
SOR-102 | SOR-102 | Phase 1 Clinical | Sorriso Pharmaceuticals Inc | Inflammatory Bowel Diseases; Colitis, Ulcerative | Details |
Kagocel | Clinical | Nearmedic Plus Llc | Respiratory Tract Infections; Respirovirus Infections; Influenza, Human | Details | |
Ustekinumab biosimilar (BioFactura) | BFI-751 | BioFactura Australia Pty Ltd | Details | ||
Brazikumab | AMG-139; MEDI-2070; Anti-IL-23-MAb (Amgen) | Phase 2 Clinical | Amgen Inc | Inflammatory Bowel Diseases; Psoriasis; Colitis, Ulcerative; Crohn Disease | Details |
mRNA-2752 | mRNA-2752 | Phase 1 Clinical | Moderna Inc, Astrazeneca Plc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
SFA-002 | SFA-002; SFA002 | Phase 1 Clinical | Arthritis, Rheumatoid; Plaque psoriasis | Details | |
IL-23/CGRP bispecific antibody (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Autoimmune Diseases | Details | |
Ustekinumab biosimilar (Curateq Biologics) | BP38; BP-38 | Phase 1 Clinical | CuraTeQ Biologics Pvt Ltd | Psoriasis | Details |
Ustekinumab Biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Autoimmune Diseases | Details | |
Ustekinumab biosimilar(Rani Therapeutics) | RT-111 | Phase 1 Clinical | Rani Therapeutics Llc | Psoriasis | Details |
SOR-102 | SOR-102 | Phase 1 Clinical | Sorriso Pharmaceuticals Inc | Inflammatory Bowel Diseases; Colitis, Ulcerative | Details |
Kagocel | Clinical | Nearmedic Plus Llc | Respiratory Tract Infections; Respirovirus Infections; Influenza, Human | Details | |
Ustekinumab biosimilar (BioFactura) | BFI-751 | BioFactura Australia Pty Ltd | Details |
This web search service is supported by Google Inc.